Expert Consulting and Modeling Services for Small Molecule Drug Discovery

Computational sciences strategy

With over 30 years of pharma experience, CognitiX Molecular possessed a depth knowledge of a broad computational techniques for small molecule drug discovery. We specializes in assessing and evaluating computational technologies with a focus on their potential impacts in practices. We emphasize human cognitive intelligence and fundamental science augmented by AI/ML techniques. We help our clients to develop strategies through internal and/or external investments to drive the medicinal chemistry and molecular design to a new level.

Strategic computational modeling for molecular design

Leverage the practical knowledge and proven impacts of computational techniques in medicine design, CognitiX Molecular provides consultation on advanced and pragmatic techniques for small drug discovery to optimize design strategy, reduce Design-Make-Test cycle time, and maximize return of investment.

Deep knowledges in molecular properties, molecular interaction to accelerate your project delivery

With a track record of contributing to design of clinical candidates for a broad range of targets in multiple disease areas and technical expertise of computational chemistry and AI/ML techniques, we provide computational modeling service to support your small molecule drug discovery effort.

About CognitiX Molecular, LLC

CognitiX Molecular is founded by Dr. Xinjun Hou, a scientist with 30+ years of industrial experience in computational and AI-powered small molecule drug discovery.

In his last role as a senior scientific director at Pfizer, Dr. Xinjun Hou built a portfolio of computational innovations through Pfizer’s Computational Chemistry Network Group and external partnerships. He spearheaded AI partnerships with PostEra, XtalPi, MIT, and University of Cambridge to build company's AI capability in molecular design, synthetic and computational chemistry. He developed strategic initiatives to strength core computational chemistry capability with XtalPi, Stanford University, and other partners to advance in crystal structure prediction (CSP), molecular mechanics force field, molecular dynamics, and potency prediction techniques.

Dr. Xinjun Hou is a devoted scientist committed to impact molecular design using computational modeling. He and his team of computational scientists deployed SBDD, LBDD, Virtual Screening, QSAR, Generative Chemistry and AI/ML models to deliver more than 20 small molecule clinical candidates of in neuroscience, cardiovascular and metabolic, and antiviral disease areas.

Dr. Xinjun Hou started his career at Agouron Pharmaceutical Inc, a pioneer in structure-based drug design in San Diego ,which was later acquired by Pfizer. He was a cofounder of SABPA, SoCal Association for Biomedical and Pharmaceutical Advancements, a 501(c)(3) nonprofit organization launched in 2002 and now has over 4,000 members and subscribers, including scholars, professionals, and entrepreneurs within Southern California's biotech and pharmaceutical industries.